PCG
DNLI icon

Private Capital Group’s Denali Therapeutics DNLI Stock Holding History

Private Capital Group’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$5K Sell
176
-16
-8% -$419 ﹤0.01% 1245
2022
Q1 		$6K Buy
192
+60
+45% +$2.06K ﹤0.01% 1436
2021
Q4 		$6K Sell
132
-167
-56% -$7.91K ﹤0.01% 1481
2021
Q3 		$15K Buy
299
+279
+1,395% +$15.7K ﹤0.01% 1191
2021
Q2 		$2K Buy
+20
New +$1.24K ﹤0.01% 1830

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Private Capital Group's DNLI Position: Q2 2022 in Review

Private Capital Group reduced its Denali Therapeutics (DNLI) stake by 8.3% in Q2 2022, selling an estimated $419 and leaving 176 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #1245.

Private Capital Group first reported a position in DNLI in Q2 2021 and has held it in 5 quarters since. The position peaked at $15K in Q3 2021. 188 funds tracked by Wall St. Rank hold DNLI as of Q2 2022.

  • Private Capital Group held 176 shares of Denali Therapeutics worth $5K as of Q2 2022.
  • Private Capital Group sold 16 Denali Therapeutics shares in Q2 2022, an estimated $419.
  • Denali Therapeutics made up ﹤0.01% of Private Capital Group's portfolio in Q2 2022, its #1245 holding.
  • Private Capital Group first reported a position in Denali Therapeutics in Q2 2021 and has held it in 5 quarters since.
  • Private Capital Group's Denali Therapeutics position peaked at $15K in Q3 2021.
  • 188 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2022.

Based on Private Capital Group's 13F filing for Q2 2022, filed 28 Jul 2022.